Identification of Splice Variants as Molecular Markers in Parkinson's Disease
Abstract
Alternative splicing is responsible for producing several products from a single transcript and can cause pathogenic changes in RNA in neurodegenerative disease. This proposal tests the hypothesis that regulation of normal splicing is disrupted in Parkinson's disease (PD). Scope: Experiments are designed to determine splicing products in the brain and blood of experimental MPTP models of PD and the blood of newly diagnosed PD patients, who are not yet on dopamine therapy. The overall goal is to use splice variants as biomarkers to identify individuals at risk for PD. To date, we have identified and quantified alternatively spliced transcripts for several candidate genes in MPTP models of PD. We have also obtained RB permission to study splicing factors in the blood of newly diagnosed PD patients. Major Findings: Mice treated chronically with MPTP show a shift in the ratio of FosB, RGS9 and Ania6 splice variants in the striatum, 3 days post-treatment. The splicing ratios for AChE and Ania 6 also change in the blood following chronic treatment and, for Ania 6, the changed ratio persists up to 3 weeks after treatment. Progress in the first year includes 4 abstracts, a peer-reviewed publication and an article in preparation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2006
- Accession Number
- ADA463435
Entities
People
- Gloria E. Meredith
Organizations
- Rosalind Franklin University of Medicine and Science